Defining minimally important differences in functional outcomes for musculoskeletal oncology patients undergoing lower extremity endoprosthetic reconstruction

Cover Letter: Young Investigator Award

I am currently a fourth-year orthopaedic surgery resident and will be undergoing a fellowship in musculoskeletal oncology at the University of Toronto in 2023-24. With respect to the current abstract, I was the lead author who conceived the idea, analyzed the data and wrote the abstract/manuscript.

Aaron M. Gazendam, MD1,2, Patricia Schneider, BSc1, Mohit Bhandari, MD, PhD1,2, Jason W. Busse, DC, PhD2, Michelle Ghert, MD, FRCSC1,2

On behalf of the PARITY Investigators

1. Division of Orthopaedic Surgery, McMaster University, Hamilton, Ontario, Canada
2. Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada

Abstract

Background: Functional outcomes are commonly reported in studies of musculoskeletal oncology patients undergoing limb salvage surgery; however, interpretation requires knowledge of the smallest amount of improvement that is important to patients – the minimally important difference (MID).

Purpose: To establish the MIDs for the Musculoskeletal Tumor Society Rating Scale-93 (MSTS-93) and Toronto Extremity Salvage Score (TESS) in patients with bone tumors undergoing lower limb salvage surgery.

Methods: This study was a secondary analysis of the recently completed PARITY (Prophylactic Antibiotic Regimens in Tumor Surgery) study evaluating patients with bone and soft tissue tumors undergoing lower extremity limb-salvage surgery and endoprosthetic reconstruction. We used MSTS-93 and TESS data from this trial to calculate: (1) the anchor-based MIDs using an overall function scale and a receiver operating curve analysis, and (2) the distribution-based MIDs based on one-half of the standard deviation of the change scores from baseline to 12-month follow-up.
**Results:** Of the 604 patients included in the PARITY trial, 591 patients had functional outcome scores available for analysis. The Pearson correlation coefficients for the association between changes in MSTS-93 and TESS scores and changes in the external anchor scores were 0.71 and 0.57, indicating “high” and “moderate” correlation. The anchor-based MID was 12 points for the MSTS-93, and 11 points for the TESS. Distribution-based MIDs were larger; 16-17 points for the MSTS-93, and 14 points for the TESS (Table 1).

**Conclusions:** The current study has established MIDs for the MSTS-93 and TESS, based on 591 patients with bone tumors undergoing lower extremity endoprosthetic reconstruction. Our estimates of MIDs for the MSTS-93 and TESS will facilitate interpretation of the importance of treatment effects, which will enable informed decision-making in trading off desirable and undesirable outcomes of alternative management strategies. The MIDs will also guide sample size calculations for subsequent studies of interventions directed at improving health-related quality of life in musculoskeletal oncology and facilitate a shift from a focus on statistical significance to patient-importance and value-based care in oncologic patients. These thresholds for minimally important improvement will also facilitate responder analyses. We suggest use of anchor-based MIDs which are grounded in changes in functional status that are meaningful to patients.

**Table 1.** Distribution and Anchor-Based Minimal Important Differences in MSTS-93 and TESS scores

<table>
<thead>
<tr>
<th>Outcome Measure</th>
<th>Distribution Based MID</th>
<th>Anchor-based MID</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0.5 SD of Preoperative Scores</td>
<td>0.5 SD of change scores from baseline-12 months</td>
</tr>
<tr>
<td>MSTS-93</td>
<td>15.8</td>
<td>16.8</td>
</tr>
<tr>
<td>TESS</td>
<td>14.2</td>
<td>14.2</td>
</tr>
</tbody>
</table>

MID = minimal important difference; MSTS-93 = Musculoskeletal Tumor Society Score; TESS = Toronto Extremity Salvage Score; SD = Standard Deviation